Journal List > Ewha Med J > v.38(1) > 1058642

TOOLS
Jung, Lim, Choi, Jang, Oh, Lee, and Cho: Ovarian Metastasis from Non-Small Cell Lung Cancer Responding to Erlotinib
Case Report

The Ewha Medical Journal 2015; 38(1): 46-49.

Published online: 26 March 2015

DOI: https://doi.org/10.12771/emj.2015.38.1.46

Ovarian Metastasis from Non-Small Cell Lung Cancer Responding to Erlotinib

Ik Ju Jung, Seung Taek Lim, Yeon Seok Choi, Tae Soo Jang, Sun Hee Oh, Joo Ah Lee, Do Yeun Cho

Department of Internal Medicine, Konyang University College of Medicine, Daejeon, Korea.

Corresponding author: Do Yeun Cho. Department of Internal Medicine, Konyang University College of Medicine, 158 Gwanjeodong-ro, Seo-gu, Daejeon 302-718, Korea. Tel: 82-42-600-9102, Fax: 82-42-600-9092, dycho@kyuh.ac.kr

Received 15 August 2014       Accepted 26 September 2014

Copyright © 2015, The Ewha Medical Journal

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Ovarian cancer is generally primary cancer and less frequently originates from metastasis from non-gynecological cancer. Ovarian metastasis from lung cancer represents only 2~4% of all ovarian metastatic cancers. We report a case of ovarian metastasis of non-small cell lung cancer with epidermal growth factor receptor mutation. The patient underwent cytoreductive surgery for the ovarian mass and erlotinib therapy for the metastatic lung cancer. Erlotinib therapy markedly decreased the size of lung mass.

Keywords: Non-small cell lung cancer, Metastasis, Erlotinib

Figures and Tables

Fig. 1

Abdomen and pelvis computed tomography. A 14.7×13.4 cm sized huge tumor of right ovary and peritoneal carcinomatosis are noted.

emj-38-46-g001
Fig. 2

Chest computed tomography. It reveals a 10×6 cm sized huge mass in left upper lung and massive right sided pleural effusion.

emj-38-46-g002
Fig. 3

Images taken after 2 cycles of gemcitabine with carboplatin chemotherapy. (A) Abdomen and pelvis computed tomography (CT) reveals increasing the size of left ovarian mass (20×14.5 cm). (B) Chest CT reveals increasing the size of left upper lung mass (12×8.2 cm).

emj-38-46-g003
Fig. 4

Immunohistochemical staining of the left ovary. (A) Cytokeratin-7 staining reveals strong reactivity (×100). (B) Thyroid transcription factor-1 staining reveals strong reactivity (×100).

emj-38-46-g004
Fig. 5

Chest CT after erlotinib chemotherapy. It reveals a marked decrease in the size of the left upper lung mass (4.2×3.7 cm).

emj-38-46-g005

References

1. Hart W. Diagnostic challenge of secondary (metastatic) ovarian tumors simulating primary endometrioid and mucinous neoplasms. Pathol Int. 2005; 55:231–243.
2. Horn L, Pao W, Johnson D. Neoplasm of the Lung. In : Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J, editors. Harrison's principles of internal medicine. 18th ed. New York: McGraw Hill;2012. p. 745–750.
3. Schiller J, Harrington D, Belani C, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346:92–98.
4. Lynch T, Bell D, Sordella R, Gurubhagavatula S, Okimoto R, Brannigan B, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefetinib. N Engl J Med. 2004; 350:2129–2139.
5. Fader A, Rose P. Role of surgery in ovarian carcinoma. J Clin Oncol. 2007; 25:2873–2883.
6. Jung YE, Lee JW, Kim BG, Bae DS. Ovarian metastasis from pulmonary adenocarcinoma. Obstet Gynecol Sci. 2013; 56:341–344.
7. Varadhachary G, Abbruzzese J. Carcinoma of Unknown Primary. In : Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J, editors. Harrison's principles of internal medicine. 18th ed. New York: McGraw Hill;2012. p. 822–823.
8. Pfister D, Johnson D, Azzoli C, Sause W, Smith T, Baker S, et al. American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004; 22:330–353.
9. Hirsch F, Varella-Garcia M, Bunn P Jr, Franklin W, Dziadziuszko R, Thatcher N, et al. Molecular predictors of outcome with gefetinib in a phase III placebo-controlled study in advanced nonsmall-cell lung cancer. J Clin Oncol. 2006; 24:5034–5042.
10. Sequist L, Bell D, Lynch T, Haber D. Molecular predictors of response to epidermal growth factor receptor antagonists in nonsmall-cell lung cancer. J Clin Oncol. 2007; 25:587–595.
TOOLS
Similar articles